Abstract

BackgroundIn past few years, long non-coding RNAs (lncRNAs) have been reported to play regulatory roles during cancer progression. LncRNA SNHG10 has been explored in several sorts of cancers. However, its detailed role and mechanism are still not well understood in glioma.MethodsExpression levels of genes were evaluated by RT-qPCR. EdU, TUNEL, sphere formation, wound healing and transwell assays appraised the effect of SNHG10 on glioma cellular processes. The interaction between molecules was examined by ChIP, RIP, RNA pull down and luciferase reporter assays.ResultsHigh level of SNHG10 was detected in glioma cells. Functional assay confirmed that SNHG10 promoted the proliferation, migration, invasion and stemness of glioma cells. Moreover, miR-532-3p was validated to bind with SNHG10 and expressed at a low level in glioma cells. Importantly, miR-532-3p exerted inhibitory functions in glioma. Furthermore, it was found that FBXL19 targeted by miR-532-3p facilitated cell growth and stemness in glioma, and that SNHG10 worked in glioma by increasing FBXL19 expression through sequestering miR-532-3p. More importantly, ETS1 promoted the transcription of SNHG10 and it mediated contribution to the malignant behaviors of glioma cells by SNHG10/miR-532-3p/FBXL19 signaling.ConclusionSNHG10 was transcriptionally activated by ETS1 and played an oncogenic role in glioma by sponging miR-532-3p and up-regulating FBXL19.

Highlights

  • In past few years, long non-coding RNAs have been reported to play regulatory roles during cancer progression

  • It was unveiled that the activities of caspase-3, caspase-8 and caspase-9 were enhanced by Small nucleolar RNA host gene 10 (SNHG10) silencing (Fig. 1f )

  • ETS Proto-Oncogene 1 (ETS1) promoted the transcription of SNHG10 in glioma we explored the upstream of SNHG10 in glioma cells

Read more

Summary

Introduction

Long non-coding RNAs (lncRNAs) have been reported to play regulatory roles during cancer progression. LncRNA SNHG10 has been explored in several sorts of cancers. Its detailed role and mechanism are still not well understood in glioma. Glioma could be classified into four grades according to malignancy and lesion location [3]. Attentions have been increasingly attached into target therapy due to the advance of scientific technology and biology. Long non-coding RNAs (lncRNAs) are identified to play crucial roles in the development of cancers [8]. Numerous lncRNAs are demonstrated to have potential values in treating tumors [9]. LncRNA PLAC2 reduced the expression of RPL36 and repressed cell cycle progression in glioma by targeting STAT1 [10].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call